As we develop new therapies, additional trials will be opened.
Clinical Trials
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/ Metastatic Solid Tumors Including Mesothelioma
MITOPE RESEARCH STUDY
ClinicalTrials.gov #NCT05278975
Currently recruiting patients
Call: +44 20 8135 8316
Email: mitope@rsoncology.com
TRIAL DESIGN:
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.
DISEASE:
-
-
Mesothelioma with malignant pleural effusion
-
Metastatic disease to the lung with malignant pleural effusion
-
Metastic ovarian and breast cancer with malignant pleural effusion
-
Research Study Locations
Principal Investigator: Nick Maskell, BMSci BM BS FRCP DM FCCP
Bristol, United Kingdom, BS105NB
stephanie.hughes@ggc.scot.nhs.uk
Principal Investigator: Kevin Blyth, MBBS
Glasgow, United Kingdom
Principal Investigator: Kevin Franks, MBChB
Leeds, United Kingdom, LS970F
Principal Investigator: Dean Fennell, FRCP PhD
Leicester, United Kingdom, LE1 5WW
Principal Investigator: Peter Szlosarek, MD PhD
London, United Kingdom, EC1A7BE
Principal Investigator: James Spicer, FRCP PhD MRCP MBBS
London, United Kingdom, SE19RT
Principal Investigator: Sanjay Popat, BSc MBBS FRCP PhD
London, United Kingdom, SW3 6JJ
Principal Investigator: Fiona Thistlethwaite, MB BChir PhD MRCP
Manchester, United Kingdom, M204BX
Principal Investigator: Avinash Aujayeb, MD
North Shields, United Kingdom, NE29 8NH
Principal Investigator: Simon Lord, BM BS MRCP PhD
Oxford, United Kingdom, OX42PG
We are pleased to partner with the following institutions who also strive to improve and expand access to care